Incretin-based drugs are important in the treatment of type 2 diabetes. However, among the incretin-based drugs, glucagon-like peptide-1 receptor agonists (GLP-1-RAs) have been reported to cause gastroesophageal reflux disease (GERD)-like symptoms making it difficult to continue treatment. Therefore, with the aim of clarifying the relationship between incretin-based drugs and GERD-like symptoms, we conducted a pharmacoepidemiological study using the Japanese adverse drug event report database (JADER).
CITATION STYLE
Noguchi, Y., Katsuno, H., Ueno, A., Otsubo, M., Yoshida, A., Kanematsu, Y., … Teramachi, H. (2018). Signals of gastroesophageal reflux disease caused by incretin-based drugs: a disproportionality analysis using the Japanese adverse drug event report database. Journal of Pharmaceutical Health Care and Sciences, 4(1). https://doi.org/10.1186/s40780-018-0109-z
Mendeley helps you to discover research relevant for your work.